Division of Genetic Medicine

Genetics and chronic pain

Polygenic risk scores — scores that reflect the influence of common genetic variants — could be used to predict the likelihood of developing chronic overlapping pain conditions and guide biomarker and targeted prevention efforts.

Research identifies new target that may prevent blood cancer

An international coalition of biomedical researchers co-led by Vanderbilt’s Alexander Bick, MD, PhD, has determined a new way to measure the growth rate of precancerous clones of blood stem cells that one day could help doctors lower their patients’ risk of blood cancer.

Inflammation implicated in exfoliation syndrome

Computational genetics tools have implicated inflammatory pathways in exfoliation syndrome, the most common cause of secondary glaucoma, which can result in blindness.

The research team included, from left, Hannah Poisner, Sydney Olson, J. Brett Heimlich, MD, PhD, Ningning Hu, MS, Alyssa Parker, Alexander Bick, MD, PhD, Joseph Van Amburg and Tara Mack.

Researchers clarify role of blood cell mutations in disease

Vanderbilt researchers have developed a new method to analyze mutations in blood stem cells that can trigger explosive, clonal expansions of abnormal cells.

The study team included, from left, Linh Tran, Ruben Barricade, PhD, Jaren Perez, and Xin Zhen. (photo by Susan Urmy)

Study reveals new genetic disorder that causes susceptibility to opportunistic infections

An international consortium co-led by Vanderbilt’s Rubén Martínez-Barricarte, PhD, has discovered a new genetic disorder that causes immunodeficiency and profound susceptibility to opportunistic infections including a life-threatening fungal pneumonia. 

Alexander Bick, MD, PhD, and colleagues are studying inflammation at the single-cell level in the rare disease RUNX1-FPD.

Chan Zuckerberg Initiative grant supports single-cell study of rare inherited disease

A multidisciplinary team led by Vanderbilt University Medical Center investigator Alexander Bick, MD, PhD, has been awarded a $2 million, four-year grant to study inflammation at the single-cell level in the rare disease RUNX1-FPD.

1 2 3 4 5 6 9